{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114196","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.696209+00:00","generated_at":"2026-06-22T08:41:50.562864+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ironwood Q3 GAAP net income $50M; LINZESS Rx demand up 10% YoY, surpasses 1M quarterly scripts","bullets":["GAAP net income of $50M ($0.28 diluted EPS); adjusted EBITDA $69M; total revenue $108.6M vs. $103.7M YoY.","LINZESS prescription demand grew 10% YoY in Q3; exceeded 1M total prescriptions in a quarter for first time.","Plan to submit sNDA to FDA for functional constipation in pediatric patients (ages 6-17) by end of 2022.","Reaffirms FY2022 guidance: total revenue $420-$430M, adjusted EBITDA >$250M, LINZESS net sales low single digit % growth.","Ended Q3 with $574M cash; no debt on balance sheet; strong liquidity position."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114196","json":"https://secwatch.observer/filing/0001104659-22-114196.json","markdown":"https://secwatch.observer/filing/0001104659-22-114196.md","text":"https://secwatch.observer/filing/0001104659-22-114196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/0001104659-22-114196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/tm2229423d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:41:50.562864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0df6f81efdcd75ac0dcb6ae6f9ba86c0604e8768","claim":"IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2022 results: revenue $108,637, net income $50,317, EPS $0.33. Guidance reaffirmed.","evidence_excerpt":"allocation continue to position our company for growth.” Third Quarter 2022 Financial Highlights 1 (in thousands, except for per share amounts) 3Q 2022 3Q 2021 Total revenues $ 108,637 $ 103,747 Total operating expenses 40,164 38,576 GAAP net income 50,317 55,845 GAAP net income per share – basic 0.33 0.34 GAAP net income per share – diluted 0.28 0.34 Adjusted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/0001104659-22-114196-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$108,637"},{"label":"Net income","value":"$50,317"},{"label":"EPS","value":"$0.33"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}